Assessing the physiological relevance of PRMT5 in CLL, we treated different CLL derived cell lines for 96 h with increasing concentrations of the PRMT5-specific inhibitor EPZ015666 and followed their metabolic activity. The gene discussed is PRMT5; the disease is B-cell chronic lymphocytic leukemia.